Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Abstract

A CYP2B6 allelic variant that is more common in African-Americans than in Europeans-Americans was associated with significantly greater efavirenz plasma exposure during HIV therapy. Inter-individual differences in metabolism may, in part, explain susceptibility to efavirenz central nervous system side effects.

References

Page 1

	Year	Citations
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection Frank J. Palella, Kathleen M. Delaney, Anne C. Moorman, New England Journal of Medicine	1998	9.5K
Mixed-Effects Models in S and S-PLUS Technometrics	2001	9.4K
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Tsutomu Shimada, Hiroshi Yamazaki, Mayumi Mimura, Journal of Pharmacology and Experimental Therapeutics	1994	2.8K
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Peter Kuehl, Jiong Zhang, Yvonne Lin, Nature Genetics Cyp3a PromotersTranscriptional RegulationPlant Gene ExpressionNatural SciencesGenetics	2001	2.2K
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven, The Lancet ThrombosisMedicineGenetic EpidemiologyHematologyHuman Polymorphism	1999	1.2K
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Richard B. Kim, Martin F. Fromm, Christoph Wandel, Journal of Clinical Investigation Oral BioavailabilityImmunologyPharmacotherapyAntiviral DrugMdr1a Gene	1998	1.1K
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults Schlomo Staszewski, Javier O Morales-Ramirez, Karen T. Tashima, New England Journal of Medicine	1999	1K
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients Catia Marzolini, Amalio Telenti, Laurent A. Décosterd, AIDS	2001	831
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study Jacques Fellay, Catia Marzolini, E. Rhiannon Meaden, The Lancet Hiv-1-infected IndividualsAntiretroviral TreatmentMedicineHuman RetrovirusImmunology	2002	661
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity Bryan A. Ward, J. Christopher Gorski, David R. Jones, Journal of Pharmacology and Experimental Therapeutics	2003	591

Page 1